Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
3.780
+0.030 (0.80%)
At close: Sep 18, 2026, 4:00 PM EDT
3.765
-0.015 (-0.40%)
After-hours: Sep 18, 2026, 6:58 PM EDT
Inventiva Employees
As of December 31, 2025, Inventiva had 77 total employees, including 69 full-time and 8 part-time employees. The number of employees decreased by 41 or -34.75% compared to the previous year.
Employees
77
Change
-41
Growth
-34.75%
Revenue / Employee
$103,094
Profits / Employee
-$5,400,017
Market Cap
875.21M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 77 | -41 | -34.75% | 69 | 8 |
| Jun 30, 2025 | 84 | - | - | 84 | 0 |
| Dec 31, 2024 | 118 | -5 | -4.07% | 114 | 4 |
| Dec 31, 2023 | 123 | 10 | 8.85% | 120 | 3 |
| Dec 31, 2022 | 113 | 8 | 7.62% | 109 | 4 |
| Dec 31, 2021 | 105 | 11 | 11.70% | 101 | 4 |
| Mar 31, 2021 | 95 | 7 | 7.95% | 95 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Wave Life Sciences | 317 |
| 4D Molecular Therapeutics | 196 |
| Rigel Pharmaceuticals | 174 |
| Olema Pharmaceuticals | 150 |
| Cybin | 100 |
| Theravance Biopharma | 90 |
| Lexicon Pharmaceuticals | 81 |
IVA News
- 4 days ago - Inventiva SA at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
- 5 days ago - Inventiva Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 5 days ago - Inventiva price target raised to $14 from $11 at Guggenheim - TheFly
- 12 days ago - RUBIS: H1 2026 Results - Strong performance leading way to upgrade of 2026 guidance - GlobeNewsWire
- 17 days ago - Inventiva Reports Final Patient Visit In Phase 3 NATiV3 Study For Lanifibranor; Topline Data In Q4 - Nasdaq
- 18 days ago - Inventiva announces last patient visit in NATiV3 trial - TheFly
- 19 days ago - Inventiva Names Chris Benecchi As COO Ahead Of Lanifibranor's Phase 3 Readout - Nasdaq
- 20 days ago - Inventiva appoints Chris Benecchi as COO - TheFly